TNFα protects tissue resident stem cells from H2O2 induced apoptosis through a novel NF-k{cyrillic}B p50/p50 homodimer mediated signaling pathway

Biochemical and Biophysical Research Communications

Volumn 371, Issue 4, 2008, Pages 626-629

  Droll, Lilly ^a   Song, Yao Hua ^a   Krohn, Alexander ^a   Muehlberg, Fabian ^a   Alt, Eckhard ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

NF B; Stem cell; TNF

Indexed keywords

FLUORESCEIN; HETERODIMER; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROTECTION; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REGENERATION; TUMOR GROWTH; ACTIVE TRANSPORT; CELL LINE; DIMERIZATION; DRUG EFFECT; METABOLISM; REGENERATION;

ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; CELL LINE; CYTOPROTECTION; DIMERIZATION; HUMANS; HYDROGEN PEROXIDE; NF-KAPPA B P50 SUBUNIT; REGENERATION; SIGNAL TRANSDUCTION; STEM CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44449117298     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.04.048     Document Type: Article

References (50)

1. Assmus B., Schachinger V., Teupe C., Britten M., Lehmann R., Dobert N., Grunwald F., Aicher A., Urbich C., Martin H., Hoelzer D., Dimmeler S., and Zeiher A.M. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106 (2002) 3009-3017
2. Perin E.C., Dohmann H.F., Borojevic R., Silva S.A., Sousa A.L., Mesquita C.T., Rossi M.I., Carvalho A.C., Dutra H.S., Dohmann H.J., Silva G.V., Belem L., Vivacqua R., Rangel F.O., Esporcatte R., Geng Y.J., Vaughn W.K., Assad J.A., Mesquita E.T., and Willerson J.T. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107 (2003) 2294-2302
3. Stamm C., Westphal B., Kleine H.D., Petzsch M., Kittner C., Klinge H., Schumichen C., Nienaber C.A., Freund M., and Steinhoff G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361 (2003) 45-46
4. Strauer B.E., Brehm M., Zeus T., Kostering M., Hernandez A., Sorg R.V., Kogler G., and Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106 (2002) 1913-1918
5. Wollert K.C., Meyer G.P., Lotz J., Ringes-Lichtenberg S., Lippolt P., Breidenbach C., Fichtner S., Korte T., Hornig B., Messinger D., Arseniev L., Hertenstein B., Ganser A., and Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364 (2004) 141-148
6. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J., and Kessler P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105 (2002) 93-98
7. Zhang M., Methot D., Poppa V., Fujio Y., Walsh K., and Murry C.E. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J. Mol. Cell. Cardiol. 33 (2001) 907-921
8. Shake J.G., Gruber P.J., Baumgartner W.A., Senechal G., Meyers J., Redmond J.M., Pittenger M.F., and Martin B.J. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann. Thorac. Surg. 73 (2002) 1919-1925 (discussion 1926)
9. Dreyer W.J., Michael L.H., West M.S., Smith C.W., Rothlein R., Rossen R.D., Anderson D.C., and Entman M.L. Neutrophil accumulation in ischemic canine myocardium. Insights into time course, distribution, and mechanism of localization during early reperfusion. Circulation 84 (1991) 400-411
10. Shappell S.B., Toman C., Anderson D.C., Taylor A.A., Entman M.L., and Smith C.W. Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J. Immunol. 144 (1990) 2702-2711
11. Kurrelmeyer K.M., Michael L.H., Baumgarten G., Taffet G.E., Peschon J.J., Sivasubramanian N., Entman M.L., and Mann D.L. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc. Natl. Acad. Sci. USA 97 (2000) 5456-5461
12. Nakano M., Knowlton A.A., Dibbs Z., and Mann D.L. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 97 (1998) 1392-1400
13. Rezzoug F., Huang Y., Tanner M.K., Wysoczynski M., Schanie C.L., Chilton P.M., Ratajczak M.Z., Fugier-Vivier I.J., and Ildstad S.T. TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and function. J. Immunol. 180 (2008) 49-57
14. Griffin G.E., Leung K., Folks T.M., Kunkel S., and Nabel G.J. Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature 339 (1989) 70-73
15. Sen R., and Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47 (1986) 921-928
16. Young K.M., Bartlett P.F., and Coulson E.J. Neural progenitor number is regulated by nuclear factor-kappaB p65 and p50 subunit-dependent proliferation rather than cell survival. J. Neurosci. Res. 83 (2006) 39-49
17. Bai X., Sadat S., Gehmert S., Alt E., and Song Y.H. VEGF receptor Flk-1 plays an important role in c-kit expression in adipose tissue derived stem cells. FEBS Lett. 581 (2007) 4681-4684
18. Sadat S., Gehmert S., Song Y.H., Yen Y., Bai X., Gaiser S., Klein H., and Alt E. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem. Biophys. Res. Commun. 363 (2007) 674-679
19. Yaoita H., and Maruyama Y. Intervention for apoptosis in cardiomyopathy. Heart Fail. Rev. 13 (2008) 181-191
20. Morishita R., Sugimoto T., Aoki M., Kida I., Tomita N., Moriguchi A., Maeda K., Sawa Y., Kaneda Y., Higaki J., and Ogihara T. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat. Med. 3 (1997) 894-899
21. Bryant D., Becker L., Richardson J., Shelton J., Franco F., Peshock R., Thompson M., and Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97 (1998) 1375-1381
22. Sivasubramanian N., Coker M.L., Kurrelmeyer K.M., MacLellan W.R., DeMayo F.J., Spinale F.G., and Mann D.L. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104 (2001) 826-831
23. Berthonneche C., Sulpice T., Boucher F., Gouraud L., de Leiris J., O'Connor S.E., Herbert J.M., and Janiak P. New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H340-H350
24. Dawn B., Guo Y., Rezazadeh A., Wang O.L., Stein A.B., Hunt G., Varma J., Xuan Y.T., Wu W.J., Tan W., Zhu X., and Bolli R. Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J. Mol. Cell. Cardiol. 37 (2004) 51-61
25. Maekawa N., Wada H., Kanda T., Niwa T., Yamada Y., Saito K., Fujiwara H., Sekikawa K., and Seishima M. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J. Am. Coll. Cardiol. 39 (2002) 1229-1235
26. Sugano M., Tsuchida K., Hata T., and Makino N. In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats. FASEB J. 18 (2004) 911-913
27. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., Djian J., Drexler H., Feldman A., Kober L., Krum H., Liu P., Nieminen M., Tavazzi L., van Veldhuisen D.J., Waldenstrom A., Warren M., Westheim A., Zannad F., and Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
28. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
29. Eddy L.J., Goeddel D.V., and Wong G.H. Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem. Biophys. Res. Commun. 184 (1992) 1056-1059
30. Dawn B., Xuan Y.T., Marian M., Flaherty M.P., Murphree S.S., Smith T.L., Bolli R., and Jones W.K. Cardiac-specific abrogation of NF-kappa B activation in mice by transdominant expression of a mutant I kappa B alpha. J. Mol. Cell Cardiol. 33 (2001) 161-173
31. Sakaguchi T., Sawa Y., Fukushima N., Nishimura M., Ichikawa H., Kaneda Y., and Matsuda H. A novel strategy of decoy transfection against nuclear factor-kappaB in myocardial preservation. Ann. Thorac. Surg. 71 (2001) 624-629 (discussion 629-630)
32. Sawa Y., Morishita R., Suzuki K., Kagisaki K., Kaneda Y., Maeda K., Kadoba K., and Matsuda H. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury. Circulation 96 (1997) II-280-II-284 (discussion II-285)
33. Tomita N., Morishita R., Tomita S., Yamamoto K., Aoki M., Matsushita H., Hayashi S., Higaki J., and Ogihara T. Transcription factor decoy for nuclear factor-kappaB inhibits tumor necrosis factor-alpha-induced expression of interleukin-6 and intracellular adhesion molecule-1 in endothelial cells. J. Hypertens. 16 (1998) 993-1000
34. Trescher K., Bernecker O., Fellner B., Gyongyosi M., Krieger S., Demartin R., Wolner E., and Podesser B.K. Adenovirus-mediated overexpression of inhibitor kappa B-alpha attenuates postinfarct remodeling in the rat heart. Eur. J. Cardiothorac. Surg. 26 (2004) 960-967
35. Wang S., Kotamraju S., Konorev E., Kalivendi S., Joseph J., and Kalyanaraman B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem. J. 367 (2002) 729-740
36. Maulik N., Sato M., Price B.D., and Das D.K. An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett. 429 (1998) 365-369
37. Morgan E.N., Boyle Jr. E.M., Yun W., Griscavage-Ennis J.M., Farr A.L., Canty Jr. T.G., Pohlman T.H., and Verrier E.D. An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann. Thorac. Surg. 68 (1999) 377-382
38. Xuan Y.T., Tang X.L., Banerjee S., Takano H., Li R.C., Han H., Qiu Y., Li J.J., and Bolli R. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ. Res. 84 (1999) 1095-1109
39. Zhang J., Ping P., Vondriska T.M., Tang X.L., Wang G.W., Cardwell E.M., and Bolli R. Cardioprotection involves activation of NF-kappa B via PKC-dependent tyrosine and serine phosphorylation of I kappa B-alpha. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H1753-H1758
40. Narula J., Pandey P., Arbustini E., Haider N., Narula N., Kolodgie F.D., Dal Bello B., Semigran M.J., Bielsa-Masdeu A., Dec G.W., Israels S., Ballester M., Virmani R., Saxena S., and Kharbanda S. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc. Natl. Acad. Sci. USA 96 (1999) 8144-8149
41. Erl W., Hansson G.K., de Martin R., Draude G., Weber K.S., and Weber C. Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ. Res. 84 (1999) 668-677
42. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., and Baldwin Jr. A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
43. Stehlik C., de Martin R., Binder B.R., and Lipp J. Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-kappa B. Biochem. Biophys. Res. Commun. 243 (1998) 827-832
44. Lee J.P., Palfrey H.C., Bindokas V.P., Ghadge G.D., Ma L., Miller R.J., and Roos R.P. The role of immunophilins in mutant superoxide dismutase-1linked familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 96 (1999) 3251-3256
45. Kerzic P.J., Pyatt D.W., Zheng J.H., Gross S.A., Le A., and Irons R.D. Inhibition of NF-kappaB by hydroquinone sensitizes human bone marrow progenitor cells to TNF-alpha-induced apoptosis. Toxicology 187 (2003) 127-137
46. Pyatt D.W., Stillman W.S., Yang Y., Gross S., Zheng J.H., and Irons R.D. An essential role for NF-kappaB in human CD34(+) bone marrow cell survival. Blood 93 (1999) 3302-3308
47. Ratajczak J., Kucia M., Reca R., Zhang J., Machalinski B., and Ratajczak M.Z. Quiescent CD34+ early erythroid progenitors are resistant to several erythropoietic 'inhibitory' cytokines; role of FLIP. Br. J. Haematol. 123 (2003) 160-169
48. Bryder D., Ramsfjell V., Dybedal I., Theilgaard-Monch K., Hogerkorp C.M., Adolfsson J., Borge O.J., and Jacobsen S.E. Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation. J. Exp. Med. 194 (2001) 941-952
49. Thanos D., and Maniatis T. NF-kappa B: a lesson in family values. Cell 80 (1995) 529-532
50. Kurland J.F., Kodym R., Story M.D., Spurgers K.B., McDonnell T.J., and Meyn R.E. NF-kappaB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J. Biol. Chem. 276 (2001) 45380-45386